Copyright
©The Author(s) 2021.
World J Hepatol. Sep 27, 2021; 13(9): 1143-1153
Published online Sep 27, 2021. doi: 10.4254/wjh.v13.i9.1143
Published online Sep 27, 2021. doi: 10.4254/wjh.v13.i9.1143
Drug | Evidence of hepatotoxicity | Probability |
Azithromycin | Liver damage is usually self-limited cholestatic hepatitis, which appears 1 wk to 3 wk after starting treatment. It may also appear after some time following medicine discontinuance. Cholestasis and elevated transaminases can persist for up to 6 mo. Despite presenting the hepatocellular and cholestatic forms of injury, cholestatic is more often related to acute liver failure, death, or liver transplantation | A |
Lopinavir/ritonavir | Clinically apparent liver disease occurs in 3% to 10% of patients. The onset of symptoms or jaundice is usually 1 wk to 8 wk, and the pattern of elevations in serum enzymes varies from hepatocellular to cholestatic or mixed. The injury is usually self-limiting; however, fatal cases have been reported | D |
Hydroxy-chloroquine | It has not been associated with significant elevations in serum enzymes during therapy for rheumatic diseases. When used in relatively high doses, it can trigger an acute liver injury with a sudden onset of fever and marked elevation of serum enzymes. Post COVID-19 data have not been assessed | C |
Tocilizumab | It has been associated with several cases of clinically apparent liver injury with jaundice. Although the liver injury was severe, it was usually self-limiting, with complete recovery within 2 mo to 3 mo. In at least one case, however, the affected patient died of liver failure. Current recommendations are patient monitoring by routine liver tests before medication. In registration trials, serum aminotransferase elevations occurred in a high proportion (10% to 50%) of patients | C |
Remdesivir | Between 10% and 50% of patients treated developed transient, mild-to-moderate serum ALT and AST elevations within 1 d to 5 d of starting therapy without changes in serum bilirubin or alkaline phosphatase levels. Elevations above 5 times ULN were reported in up to 9% of patients in several clinical trials, but the abnormalities resolved with discontinuance and were not associated with a clinically apparent injury | D |
Nevirapine | Associated with significant elevations in ALT (above 5 times the ULN) in 4% to 20% of patients and symptomatic elevations in 1% to 5% | A |
Ivermectin | Associated with minor, self-limiting elevations in serum aminotransferase and sporadic cases of clinically apparent liver damage. Post COVID-19 data have not been assessed | D |
- Citation: Ortiz GX, Lenhart G, Becker MW, Schwambach KH, Tovo CV, Blatt CR. Drug-induced liver injury and COVID-19: A review for clinical practice. World J Hepatol 2021; 13(9): 1143-1153
- URL: https://www.wjgnet.com/1948-5182/full/v13/i9/1143.htm
- DOI: https://dx.doi.org/10.4254/wjh.v13.i9.1143